From SYMPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go?

被引：25

作者：

Pathak, Atul ^{[1
]}

Ewen, Sebastian ^{[2
]}

Fajadet, Jean ^{[3
]}

Honton, Benjamin ^{[3
]}

Mahfoud, Felix ^{[2
]}

Marco, Jean ^{[4
]}

Schlaich, Markus ^{[5
,6
]}

Schmieder, Roland ^{[7
]}

Tsioufis, Konstantinos ^{[8
]}

Ukena, Christian ^{[2
]}

Zeller, Thomas ^{[9
]}

机构：

[1] Univ Toulouse 3, CHU Toulouse, Serv Pharmacol Clin, Unite Pharmacol Cardiovasc & Autonome,INSERM 1048, F-31432 Toulouse, France

[2] Univ Klinikum Saarlandes, Klin Innere Med Kardiol Angiol & Internist Intens, Homburg, Germany

[3] Clin Pasteur, Cardiovasc Unit, Toulouse, France

[4] PCR, Toulouse, France

[5] Monash Univ, Baker IDI Heart & Diabet Inst, Neurovasc Hypertens & Kidney Dis & Human Neurotra, Melbourne, Vic 3004, Australia

[6] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic 3004, Australia

[7] Univ Hosp Erlangen, Erlangen, Germany

[8] Univ Athens, Hippokrat Hosp, Cardiol Clin 1, Athens, Greece

[9] Univ Herzzentrum Freiburg Bad Krozingen, Klin Kardiol & Angiol 2, Bad Krozingen, Germany

来源：

EUROINTERVENTION | 2014年 / 10卷 / 01期

关键词：

D O I：

10.4244/EIJV10I1A4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：21 / 23

页数：3

共 50 条

[21] Renal Denervation after Symplicity HTN-3: An Update
Persu, Alexandre
Jin, Yu
Elmula, Fadl Elmula Mohamed Fadl
Jacobs, Lotte
Renkin, Jean
Kjeldsen, Sverre
CURRENT HYPERTENSION REPORTS, 2014, 16 (08)
[22] ColVI myopathies: where do we stand, where do we go?
Allamand, Valerie
Brinas, Laura
Richard, Pascale
Stojkovic, Tanya
Quijano-Roy, Susana
Bonne, Gisele
SKELETAL MUSCLE, 2011, 1
[23] Investigative dermatology: where do we stand and where do we go?
Maurer, M.
von Stebut, E.
EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
[24] Rye and health - Where do we stand and where do we go?
Jonsson, Karin
Andersson, Roger
Knudsen, Knud Erik Bach
Hallmans, Goran
Hanhineva, Kati
Katina, Kati
Kolehmainen, Marjukka
Kyro, Cecilie
Langton, Maud
Nordlund, Emilia
Laerke, Helle Nygaard
Olsen, Anja
Poutanen, Kajsa
Tjonneland, Anne
Landberg, Rikard
TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
[25] ColVI myopathies: where do we stand, where do we go?
Valérie Allamand
Laura Briñas
Pascale Richard
Tanya Stojkovic
Susana Quijano-Roy
Gisèle Bonne
Skeletal Muscle, 1
[26] Renal Denervation for Resistant Hypertension: Where Do We Stand?
Bo Liang
Yu-Xiu Zhao
Ning Gu
Current Hypertension Reports, 2020, 22
[27] Opportunities and Limitations of Renal Denervation: Where Do We Stand?
Rodriguez, Beatriz Castillo
Secemsky, Eric A.
Swaminathan, Rajesh V.
Feldman, Dmitriy N.
Schlaich, Markus
Battaglia, Yuri
Filippone, Edward J.
Krittanawong, Chayakrit
AMERICAN JOURNAL OF MEDICINE, 2024, 137 (08): : 712 - 718
[28] Renal Denervation for Resistant Hypertension: Where Do We Stand?
Liang, Bo
Zhao, Yu-Xiu
Gu, Ning
CURRENT HYPERTENSION REPORTS, 2020, 22 (10)
[29] Biologics in vasculitides: Where do we stand, where do we go from now?
Pazzola, Giulia
Muratore, Francesco
Pipitone, Nicolo
Salvarani, Carlo
PRESSE MEDICALE, 2015, 44 (06): : E231 - E239
[30] Phage susceptibility testing methods or 'phagograms': where do we stand and where should we go?
Kolenda, Camille
Jourdan, Julie
Roussel-Gaillard, Tiphaine
Medina, Mathieu
Laurent, Frederic
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (11) : 2742 - 2749

← 1 2 3 4 5 →